ClinicalTrials.gg
CompletedNCT03697187Updated Apr 5, 2024

Patient Registry to Evaluate the Real-world Safety of Ruconest®

An observational study in Hereditary Angioedema, sponsored by Pharming Technologies B.V.. Completed at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
152
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Started
2018
with 5 others
Observational
7 of 84
2 open now
Registered
39th of 84
by date
Lead sponsor
4 of 84
Pharming Technologies B.V.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is one of 6 that started in 2018, is one of 7 observational ones, and was the 39th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.

Read the detailed description

See below.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • Hereditary Angioedema
  • HAE
  • Ruconest
  • rhC1INH
  • Registry
  • Pharming
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible patients will be 13 years of age and older, have a current diagnosis of HAE for which they have been prescribed and are currently being treated with Ruconest.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient provides as documented on the Institutional Review Board (IRB) approved informed consent document (ICF). For patients aged between 13 and 17 years old, the method of consent with or without assent will be determined by the IRB.
  2. Patient is male or female and at least 13 years of age at the time of providing consent / assent.
  3. Patient has been prescribed Ruconest for HAE.

Exclusion criteria

Exclusion Criteria:

  1. Patient is receiving HAE therapy as part of a clinical trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
152 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Hereditary Angioedema

    Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).

    Drug: rhC1INH

Interventions

  • Recombinant human C1 inhibitor

    Also known as: Ruconest

06

What researchers measure

Primary outcomes

  1. Safety analysis will consist of AEs reported per patient for up to 30 days after each single or repeated dose of Ruconest.

    In addition, extent of exposure to Ruconest and concomitant medications taken for HAE will be summarized. Concomitant medications will be limited to those specifically indicated for treatment AEs or treatment of symptoms of HAE, for example C1-inhibitors, epinephrine, IV fluids, etc. AEs will be summarized as incidence per 10,000 person-days where each patient counts only once for multiple events of the same System Organ Class and preferred terms within the 30-day evaluation period. The person-time duration for each AE for each patient is the time period (in days) between the dose of Ruconest and AE onset.

    Time frame: 3 years

Secondary outcomes

  1. AEs occurring during pregnancy or lactation and for breastfed infants will be summarized separately using the same methods as described in the primary outcome measure.

    Any pregnant woman who treats with Ruconest while on the Registry will be followed up to twelve weeks post-delivery or termination. Those treated with Ruconest while actively nursing will be followed until end of lactation.

    Time frame: 3 years

07

Study locations

1 site
  • The US Hereditary Angioedema Association
    Fairfax, Virginia 22030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jun 2021, 36 months.

Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Oct 5, 2018
StartActual
Jun 30, 2018
Primary completionActual
Jun 30, 2021
CompletionActual
Jul 31, 2021
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03697187
Collaborators
US Hereditary Angioedema Association
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Jun 30, 2018
Primary completion
Jun 30, 2021
Completion
Jul 31, 2021
Last update
Apr 5, 2024

Study contacts

Anurag Relan, MD
study director · Pharming Technologies BV

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion